Related Experiment Videos

Low-dose spironolactone in the management of resistant hypertension: a surveillance study

Deirdre A Lane1, Sarah Shah, D Gareth Beevers

  • 1University Department of Medicine, City Hospital, Birmingham, UK.

Journal of Hypertension
|March 14, 2007
PubMed

Insights

Low-dose spironolactone effectively manages resistant hypertension when added to existing therapies, including angiotensin-blocking drugs. Careful monitoring of electrolytes is crucial for patient safety and treatment success.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Resistant hypertension poses a significant challenge in cardiovascular disease management.
  • Patients with resistant hypertension often require multiple antihypertensive agents.

Purpose of the Study:

  • To evaluate the efficacy of low-dose spironolactone as an add-in therapy for patients with resistant hypertension.
  • To assess the impact of spironolactone on blood pressure control in this patient population.

Main Methods:

  • An open observational study was conducted.
  • 133 patients with resistant hypertension, already on angiotensin-blocking drugs and other therapies, were included.
  • Spironolactone was administered at doses of 25-50 mg.

Main Results:

  • Outcome data were available for 119 patients.
  • Spironolactone (median dose 25 mg) addition resulted in a significant mean reduction in systolic blood pressure (21.7 mmHg) and diastolic blood pressure (8.5 mmHg).
  • A mean increase of 0.3 mmol/l in serum potassium was observed, with two patients discontinuing the drug due to elevated potassium levels (>6.0 mmol/l).

Conclusions:

  • Low-dose spironolactone is an effective add-in treatment for hypertension resistant to regimens including angiotensin-blocking agents.
  • Careful monitoring of plasma electrolytes is essential for safe and effective spironolactone use in resistant hypertension.
Abstract

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...